FindTrial
Sign In

Low intensity laser therapy associated with Chamomile and Calendula in the treatment of oral Mucositis

Low intensity laser associated with matricaria recutita linn and calendula officinalis in the treatment of oral Mucositis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-7vgnk2
Enrollment
Unknown
Registered
2018-12-26
Start date
2019-01-10
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral mucositis

Interventions

A prospective, randomized, double blind controlled clinical study will be conducted. In this study, 60 patients, aged between 12 and 19 years, with grade II oral mucositis will be evaluated. The sampl
Group two will use only the low intensity laser
Group three will use only the chamomile spray
Group four will use the low-intensity laser plus chamomile
Group five will use only the marigold spray, while group six will use the calendula with the low intensity laser. A handling pharmacy will be responsible for the manufacture of chamomile and calendula
Device
E02.594.540
B01.650.940.800.575.100.100.195.488
B01.650.940.800.575.100.100.141

Sponsors

Fundação Valeparaibana de Ensino
Lead Sponsor
Universidade do Vale do Paraíba
Collaborator

Eligibility

Age
19 Years to 30 Years

Inclusion criteria

Inclusion criteria: Age between 19 and 30 years; presence of oral mucositis grade; patients receiving similar treatment protocols; patients able to cooperate with the protocol established by the research; patients capable of performing the oral hygiene protocol; patients who accept the terms proposed in this study and sign the informed consent form.

Exclusion criteria

Exclusion criteria: Patients who present some allergic reaction to any of the plants used in this study, or have a history of any adverse reaction to the family Asteraceae or Compositae, will be excluded; Receiving oral or intravenous anticoagulant therapy; Use topical or systemic therapy with anti-inflammatories; receive another type of standard or experimental protocol for the treatment of oral mucositis.

Design outcomes

Primary

MeasureTime frame
The patient's pain reduction is expected to be evidenced by the visual analog scale for pain, a scale that graduates oral mucositis. Measurements will be made at the beginning and at the end of treatment.—

Secondary

MeasureTime frame
The gradual reduction of oral mucositis, measured by the visual analogue scale, is expected. Evaluation of outcomes will be performed at the end of treatment.—

Countries

Brazil, Brunei Darussalam

Contacts

Public ContactVânia Silva Gomes

Universidade do Vale do Paraíba

vaniathais02@hotmail.com55 (12)3028-3659

Outcome results

None listed

Source: REBEC (via WHO ICTRP)